NCT07767175PHASE1RecruitingAccepts Healthy Volunteers
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
Novo Nordisk A/S
Start Date
8/12/2026
Completion Date
9/23/2027
Summary
The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.
Eligibility Criteria
Age Range: 18 years to 55 years
Inclusion Criteria:
* Male or female (sex at birth).
* Age 18-55 years (both inclusive) at the time of signing informed consent.
* Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator.
* Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator.
Exclusion Criteria:
* Known or suspected hypersensitivity to study intervention(s) or related products.
* Previous randomisation in this study.
* History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions.
* Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception.
* Current participation (signed informed consent) in any other interventional clinical study.
* Exposure to an investigational medicinal product within 30 days or five half-lives of that product (whichever is longer) before screening.
* Any disorder, unwillingness or inability which, in the investigator's opinion, might jeopardise participant safety or compliance with the protocol.
* Glycated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 percentage (%) (48 millimoles per mole \[mmol/mol\]) at screening.
Interventions
DRUG
NNC0721-8060
DRUG
Semaglutide
DRUG
Placebo
Conditions
OverweightObesity
Locations
ICON Early Phase Services, LLC
Lenexa, Kansas 66219
United States
ICON
San Antonio, Texas 78209
United States